Abstract
The insulin-like growth factor I receptor (IGF-IR) pathway plays a major role in cancer growth, tumor cell survival and resistance to therapy. Ancillary evidence that targeting the IGF-IR may be useful in the treatment of cancer has been accumulating for almost two decades. Today, more than two dozen compounds have been developed and clinical trials are underway for at least 12 of those. The ability to pharmacologically control the IGF-IR pathway holds not only promising therapeutic implications but also the possibility to gather a better understanding of the role of the IGF axis in tumor initiation and progression. This review focuses on the preclinical rationale for targeting the IGF-IR and other components of the IGF-I system, early clinical results observed to date, biomarker approaches employed and the lessons from these early results for future study design. Early clinical trials reveal an acceptable safety profile together with pharmacodynamic evidence of receptor targeting. Instances of single-agent activity during phase I evaluations have been well documented and a recently reported randomized phase II study indicates that co-administration of an anti-IGF-IR antibody with chemotherapy improves objective response rate and progression-free survival in non-small cell lung cancer patients. These early results support ongoing research across a broad range of cancer indications.
Keywords: A12, cixutumumab, AMG-479, AVE1642, AXL1717, BIIB022, BMS-754807, CP-751,871, figitumumab, MK0646
Current Drug Targets
Title: Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Volume: 10 Issue: 10
Author(s): Antonio Gualberto and Michael Pollak
Affiliation:
Keywords: A12, cixutumumab, AMG-479, AVE1642, AXL1717, BIIB022, BMS-754807, CP-751,871, figitumumab, MK0646
Abstract: The insulin-like growth factor I receptor (IGF-IR) pathway plays a major role in cancer growth, tumor cell survival and resistance to therapy. Ancillary evidence that targeting the IGF-IR may be useful in the treatment of cancer has been accumulating for almost two decades. Today, more than two dozen compounds have been developed and clinical trials are underway for at least 12 of those. The ability to pharmacologically control the IGF-IR pathway holds not only promising therapeutic implications but also the possibility to gather a better understanding of the role of the IGF axis in tumor initiation and progression. This review focuses on the preclinical rationale for targeting the IGF-IR and other components of the IGF-I system, early clinical results observed to date, biomarker approaches employed and the lessons from these early results for future study design. Early clinical trials reveal an acceptable safety profile together with pharmacodynamic evidence of receptor targeting. Instances of single-agent activity during phase I evaluations have been well documented and a recently reported randomized phase II study indicates that co-administration of an anti-IGF-IR antibody with chemotherapy improves objective response rate and progression-free survival in non-small cell lung cancer patients. These early results support ongoing research across a broad range of cancer indications.
Export Options
About this article
Cite this article as:
Gualberto Antonio and Pollak Michael, Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology, Current Drug Targets 2009; 10 (10) . https://dx.doi.org/10.2174/138945009789577945
DOI https://dx.doi.org/10.2174/138945009789577945 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial: Overview on microRNAs in Cancer Development and Virus Infection
MicroRNA FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes
Current Radiopharmaceuticals Prostate-Specific G-Protein Coupled Receptor, an Emerging Biomarker Regulating Inflammation and Prostate Cancer Invasion
Current Molecular Medicine Prospective Plant Based Anticancer Lead Molecules
Current Topics in Medicinal Chemistry Regulation of Cell Death and Survival by Resveratrol: Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Experience with Indium-111 and Yttrium-90-Labeled Somatostatin Analogs
Current Pharmaceutical Design Metabolite Identification in NMR-based Metabolomics
Current Metabolomics Targeting Matrix Metalloproteinases in Inflammatory Conditions
Current Drug Targets Distinct Functions of Retinoic Acid Receptor Beta Isoforms: Implications for Targeted Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemical Constituents of Plants from the Genus Valeriana
Mini-Reviews in Organic Chemistry Genes Associated with Epithelial-Mesenchymal Transition: Possible Therapeutic Targets in Ductal Pancreatic Adenocarcinoma?
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs and Lung Cancer: New Oncogenes and Tumor Suppressors, New Prognostic Factors and Potential Therapeutic Targets
Current Medicinal Chemistry Folate Nutrigenetics: A Convergence of Dietary Folate Metabolism, Folic Acid Supplementation, and Folate Antagonist Pharmacogenetics
Drug Metabolism Letters Recent Patents on Devices and Technologies for Early Cancer Diagnostics
Recent Patents on Biomedical Engineering (Discontinued) The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology Molecular Mechanisms of Anti-cancer Activities of β-elemene: Targeting Hallmarks of Cancer
Anti-Cancer Agents in Medicinal Chemistry Innovative Strategies in In Vivo Apoptosis Imaging
Current Medicinal Chemistry Killer Beacons for Combined Cancer Imaging and Therapy
Current Medicinal Chemistry Novel Therapies Against Aggressive and Recurrent Epithelial Cancers by Molecular Targeting Tumor- and Metastasis-Initiating Cells and Their Progenies
Anti-Cancer Agents in Medicinal Chemistry Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications
Current Pharmaceutical Biotechnology